Priority Lists
Protocol Posting of
Activations
A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with "No Evidence of Disease" after Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma
| Action Codes | IP, AC, ER |
| Study Coordinator(s) | Kim A. Margolin, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists |
Closures
Amendments, Revisions, Memoranda
Revision #1
Evaluation of Interferon Alpha-2b and Thalidomide in Patients with Disseminated Malignant Melanoma, Phase II
| Study Coordinator(s) | Laura F. Hutchins, M.D., Joseph I. Clark, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Revision #4
Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary
| Study Coordinator(s) | Cheryl L. Willman, M.D., Jerald P. Radich, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, CTSU, Affiliates |
Revision #9
Cytogenetic, Molecular and Cellular Biology Studies in Metastatic Melanoma Patients, Ancillary
| Study Coordinator(s) | Jeffrey A. Sosman, M.D., Vernon K. Sondak, M.D., Ralph J. Tuthill, M.D., Cecilia M. Fenoglio-Preiser, M.D., Marilyn L. Slovak, Ph.D., Robert P. Whitehead, M.D., Diane L. Persons, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, ECOG |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required